Canaccord Genuity Group Analysts Give Knight Therapeutics (TSE:GUD) a C$6.50 Price Target

Canaccord Genuity Group set a C$6.50 target price on Knight Therapeutics (TSE:GUD) in a research report report published on Friday morning, Marketbeat.com reports. The brokerage currently has a buy rating on the stock.

GUD has been the subject of a number of other research reports. Stifel Nicolaus increased their price objective on Knight Therapeutics from C$6.25 to C$7.45 and gave the stock a “buy” rating in a report on Tuesday, March 25th. Research Capitl raised Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 11th. Two research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Strong Buy” and an average target price of C$7.15.

Knight Therapeutics Price Performance

The business has a 50 day simple moving average of C$5.89 and a two-hundred day simple moving average of C$5.60. Knight Therapeutics has a 52 week low of C$5.09 and a 52 week high of C$6.45. The stock has a market capitalization of C$577.57 million, a price-to-earnings ratio of -19.06, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The company has a debt-to-equity ratio of 7.52, a current ratio of 3.36 and a quick ratio of 1.79.

Insiders Place Their Bets

In related news, insider Sime Armoyan acquired 17,600 shares of the stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average cost of C$5.48 per share, with a total value of C$96,488.48. Over the last three months, insiders have sold 3,143,300 shares of company stock valued at $19,733,740. Insiders own 45.62% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.